Pharmacy valuation: EBITDA and the NHS contract

Valued on earnings, not shelves

A community pharmacy is valued primarily on its earnings, usually expressed as a multiple of EBITDA, rather than on the value of its stock or fittings. EBITDA stands for earnings before interest, tax, depreciation and amortisation, and for a pharmacy it captures the gross profit left after staff costs and running costs. The NHS dispensing contract is central to that, because for most pharmacies the bulk of income flows from dispensing and associated NHS services.

This means a pharmacy acquisition is the purchase of a trading business with a regulated income stream rather than a simple property deal. The location, prescription volume, opening hours, local competition and the mix of NHS and retail income all influence both the valuation and the multiple a buyer will pay. A pharmacy valuation therefore looks behind the headline turnover to the durability of the underlying earnings.

The multiple itself reflects how secure and how growing those earnings are. A pharmacy with rising prescription volumes, a settled team and a diverse prescribing base attracts a higher multiple than one that is static or dependent on a single surgery. Buyers will pay more for a business that looks set to grow and less for one carrying obvious risk, so two pharmacies with similar turnover can be worth quite different amounts once the quality of the income is taken into account.

What drives a pharmacy valuation

Several financial and operational factors move the value. Prescription volume and its trend show whether the business is growing or shrinking. The NHS contract and the local demographics indicate how secure that volume is. Staff costs, including whether the pharmacy depends on expensive locum cover, affect the profit that reaches EBITDA. Goodwill and any intangible value, such as a strong local reputation or a nearby surgery relationship, add to the price a buyer will accept.

Buyers and lenders also weigh risk. A pharmacy heavily reliant on one prescribing surgery carries more risk than one drawing from several, and that feeds into both the multiple and the lending appetite. Some sellers use a valuation calculator for a rough figure, but a credible valuation looks at the real accounts, the contract and the location rather than a single input.

Buying or selling a pharmacy

The same valuation that guides a buyer also matters when selling a pharmacy. An owner thinking of selling will want a realistic view of the price before taking the pharmacy business to market, and pharmacy buyers will assess that figure against the earnings and the risk. Pharmacies for sale that come to market with clean accounts and a clear EBITDA picture attract more interest and tend to achieve a stronger price, so preparation pays whichever side of the deal you are on.

The valuation process is much the same whether you are buying or preparing to sell your pharmacy: gather the accounts and prescription data, apply the EBITDA multiple, then sense-check it against the contract, the location and recent pharmacy sales. For a buyer, the valuation is what the finance is built on; for a seller, it sets the asking price and frames negotiations. Either way, an experienced view of the pharmacy business, its contract income and its location underpins a credible figure. We work with buyers acquiring a pharmacy, and the same understanding of value helps owners who want to know where they stand before they decide to sell.

Financing an acquisition or refinance

We arrange acquisition and refinance funding for community pharmacies. Because value is tied to EBITDA and contract income, lenders assess the durability of those earnings and the experience of the buyer. A pharmacy with steady prescription volumes, clean accounts and a sensible cost base presents well, and that strengthens the price and the funding available.

Whether you are a first-time owner, an existing pharmacist adding a second site, or a group consolidating several pharmacies, the funding is shaped around the earnings the business generates. Where the premises are leased, the lease terms form part of the picture; where there is a freehold, that property value can support the structure alongside the goodwill.

Location, lease and the wider picture

Location is one of the strongest drivers of a pharmacy valuation. A site next to a busy surgery, in a growing area, or with limited nearby competition draws steady prescription volume, while an isolated or declining location carries more risk. Buyers and lenders look at the local demographics and the prescribing base behind the pharmacy, because they show how secure the dispensing income is over time.

The premises matter too. Where the pharmacy is leased, the length and terms of the lease affect both the value and the funding, because a short lease can undermine a buyer's confidence and a lender's security. Where there is a freehold, that property value can support the structure alongside the goodwill. A pharmacy with a strong location, a sound lease or freehold, and growing volumes presents as a lower-risk investment, which feeds through to a better price and better terms.

Preparing for the lender

Have your accounts, prescription volume data and details of the NHS contract ready. Lenders will want to understand how resilient the income is, what would happen if a nearby surgery moved or closed, and how you intend to run the pharmacy after completion. A clear view of staff costs and any locum reliance helps too, because it shows the true earnings the loan is serviced from.

Take professional advice on the valuation and the deal structure before you commit. A well-prepared case, with the financial position evidenced, is what turns an indicative figure into firm terms.

Commercial finance of this kind is not regulated by the Financial Conduct Authority. Any rates or terms are indicative and subject to status, valuation and full lender approval. This is general information, not financial advice; take independent professional advice before borrowing.